Vaxcyte Inc. Common Stock vs D Wave Quantum Inc — how do they compare? Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B), while D Wave Quantum Inc trades at $11.85 (market cap $5.08B). The key difference: Vaxcyte Inc. Common Stock is far larger — about 2.1× D Wave Quantum Inc's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, D Wave Quantum Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and D Wave Quantum Inc for 33 Days on average.
| PCVX | QBTS | |
|---|---|---|
Market Cap | $10.51B | $5.08B |
Volume | 2,644,694 | 11,653,341 |
Sector | Health | Technology |
52-Week High | $73.82 | $44.78 |
52-Week Low | $40.32 | $12.03 |
Typical Hold Time | 0 Days | 33 Days |
Enterprise Value | $9.14B | $4.58B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
QBTS (D-Wave Quantum Inc.) trades at $13.38, down 2.62% on the day, reflecting a bearish technical trend amid negative earnings and high valuation metrics. The company reported a net loss of $355.06M on $24.59M revenue for 2025, with a net income margin of -2,001.59%. Recent news highlights ongoing fraud investigations by multiple law firms, though the company continues to advance its quantum computing technology, such as the launch of a gate-model simulator beta program.
The stock presents a high-risk, speculative opportunity with a unanimous analyst buy rating and a consensus price target of $34.38, implying significant upside. However, substantial financial losses, negative cash flow from operations, and legal uncertainties pose severe risks. Investors should weigh the long-term potential of quantum computing against immediate financial instability and litigation overhangs.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →